Apr 6, 2026 08:00AM
Feb 4, 2026 08:32AM
Feb 4, 2026 08:30AM
May 6, 2025 04:01PM
Apr 17, 2025 07:01AM
Apr 17, 2025 07:00AM
May 28, 2024 08:45AM Aprea Therapeutics (APRE) Announces SRC Endorsed Dosing of Patients with ATRN-119
May 28, 2024 08:45AM
May 14, 2024 08:30AM
May 13, 2024 04:01PM
May 2, 2024 09:15AM
May 2, 2024 09:15AM
Apr 10, 2024 12:00PM
Mar 26, 2024 07:45AM Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Mar 11, 2024 08:30AM
Mar 11, 2024 08:30AM
Mar 11, 2024 08:29AM
Mar 11, 2024 08:29AM
Feb 6, 2024 08:01AM
Feb 6, 2024 08:01AM
Jan 30, 2024 08:00AM Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
Jan 4, 2024 04:06PM
Jan 4, 2024 04:05PM
Nov 9, 2023 04:05PM
Mar 30, 2023 04:05PM
Mar 30, 2023 04:05PM
Aug 11, 2022 04:15PM
Aug 11, 2022 04:15PM Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
Mar 15, 2022 04:15PM
Mar 15, 2022 04:15PM
Jan 6, 2022 08:00AM
Dec 14, 2021 08:00AM
Dec 14, 2021 08:00AM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematol
Dec 13, 2021 08:00AM
Dec 9, 2021 08:00AM
Dec 9, 2021 08:00AM
Dec 9, 2021 08:00AM
Nov 8, 2021 04:15PM
Nov 8, 2021 04:15PM
Nov 4, 2021 04:15PM Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
Nov 4, 2021 04:15PM
Sep 21, 2021 09:21AM
Sep 20, 2021 06:47PM
Sep 20, 2021 04:15PM
Sep 20, 2021 04:15PM
Sep 14, 2021 08:00AM
Sep 14, 2021 08:00AM Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
Aug 12, 2021 04:15PM

322,199 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All